Pharma’s next big leap won’t come from the lab. It’ll come from outside the lab, where the rules of narrative, attention, and ...

According to the company, H1 net sales growth was driven by continued global demand for key medicines, including JARDIANCE, a ...

AbbVie has secured UK marketing authorisation for ELAHERE (mirvetuximab soravtansine), the first antibody-drug conjugate (ADC ...

On day three of BIO 2025, editor-in-chief Jonah Comstock caught up with OS Therapies CEO Paul Romness and EVERSANA VP of ...

June was a slower month on the pharma agency side, but were several hires worth reporting, as well as a couple of interesting ...

Researchers at the University of Florida have developed a new mRNA-based vaccine that, when combined with checkpoint ...

An antibody being developed by AstraZeneca for the treatment of light chain (AL) amyloidosis has failed to move the needle in ...

EVERSANA has launched a new pharmacovigilance (PV) platform that answers the need to apply advanced data analytics and ...

This month’s executive moves span a diverse range of organisations – from CDMOs and genomics platforms to diagnostics and ...

Alexion, the rare disease unit acquired by AstraZeneca nearly five years ago, has announced high-level positive results from ...

The new approval will help Merck make a return on its $3.9 billion investment in acquiring SpringWorks, which has operated as ...

The FDA appears to have won its staring contest with Sarepta over shipments of Elevidys, after the company blinked and agreed ...